Reversible and regionally selective downregulation of brain cannabinoid CB 1 receptors in chronic daily cannabis smokers

Molecular Psychiatry

Volumn 17, Issue 6, 2012, Pages 642-649

  Hirvonen, J ^a   Goodwin, R S ^b   Li, C T ^a   Terry, G E ^a   Zoghbi, S S ^a   Morse, C ^a   Pike, V W ^a   Volkow, N D ^b   Huestis, M A ^b   Innis, R B ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

addiction; cannabis; CB1 receptor; positron emission tomography; receptor imaging

Indexed keywords

CANNABINOID 1 RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; BRAIN CORTEX; BRAIN REGION; CANNABIS SMOKING; CHILD; CONTROLLED STUDY; CORRELATIONAL STUDY; HUMAN; MALE; MEDICAL RESEARCH; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SCHOOL CHILD; SMOKING CESSATION;

ADULT; CEREBRAL CORTEX; DOWN-REGULATION; FLUORINE RADIOISOTOPES; FUNCTIONAL NEUROIMAGING; HUMANS; MALE; MARIJUANA SMOKING; POSITRON-EMISSION TOMOGRAPHY; PYRROLIDINONES; RECEPTOR, CANNABINOID, CB1; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS;

EID: 84861456223     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2011.82     Document Type: Article

References (42)

1. Degenhardt L, Chiu WT, Sampson N, Kessler RC, Anthony JC, Angermeyer M et al. Toward a global view of alcohol, tobacco, cannabis, and cocaine use: findings from the WHO World Mental Health Surveys. PLoS Med 2008; 5: e141.
2. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet 2009; 374: 1383-1391.
3. Jones RT, Benowitz NL, Herning RI. Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol 1981; 21: 143S-152S.
4. D'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T et al. Blunted psychotomimetic and amnestic effects of D-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 2008; 33: 2505-2516.
5. Ramaekers JG, Kauert G, Theunissen EL, Toennes SW, Moeller MR. Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J Psychopharmacol 2009; 23: 266-277.
6. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. Abstinence symptoms following smoked marijuana in humans. Psychopharmacology (Berl) 1999; 141: 395-404. (Pubitemid 29190008)
7. Cooper ZD, Haney M. Actions of delta-9-tetrahydrocannabinol in cannabis: relation to use, abuse, dependence. Int Rev Psychiatry 2009; 21: 104-112.
8. Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET et al. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 2001; 58: 322-328. (Pubitemid 32299527)
9. Huestis MA, Boyd SJ, Heishman SJ, Preston KL, Bonnet D, Le Fur G et al. Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology (Berl) 2007; 194: 505-515. (Pubitemid 47492992)
10. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990; 87: 1932-1936.
11. Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997; 77: 299-318. (Pubitemid 27079604)
12. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161-202. (Pubitemid 34575709)
13. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science 2002; 296: 678-682.
14. Gonzalez S, Cebeira M, Fernandez-Ruiz J. Cannabinoid tolerance and dependence: a review of studies in laboratory animals. Pharmacol Biochem Behav 2005; 81: 300-318. (Pubitemid 40807129)
15. Sim-Selley LJ. Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol 2003; 15: 91-119. (Pubitemid 38160440)
16. Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Vogt LJ, Sim-Selley LJ. Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. J Neurochem 1999; 73: 2447-2459.
17. Oviedo A, Glowa J, Herkenham M. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. Brain Res 1993; 616: 293-302. (Pubitemid 23200058)
18. Sim-Selley LJ, Martin BR. Effect of chronic administration of R- (+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3- de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta 9-tetrahydrocannabinol on cannabinoid receptor adaptation in mice. J Pharmacol Exp Ther 2002; 303: 36-44.
19. Breivogel C, Scates SM, Beletskaya IO, Lowery OB, Aceto MD, Martin BR. The effects of D9-tetrahydrocannabinol physical dependence on brain cannabinoid receptors. Eur J Pharmacol 2003; 459: 139-150. (Pubitemid 36078314)
20. Sim-Selley LJ, Schechter NS, Rorrer WK, Dalton GD, Hernandez J, Martin BR et al. Prolonged recovery rate of CB1 receptor adaptation after cessation of long-term cannabinoid administration. Mol Pharmacol 2006; 70: 986-996. (Pubitemid 44268455)
21. McKinney DL, Cassidy MP, Collier LM, Martin BR, Wiley JL, Selley DE et al. Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to 9-tetrahydrocannabinol. J Pharmacol Exp Ther 2008; 324: 664-673. (Pubitemid 351185869)
22. Terry GE, Hirvonen J, Liow JS, Zoghbi SS, Gladding R, Tauscher JT et al. Imaging and quantitation of cannabinoid CB1 receptors in human and monkey brains using (18)F-labeled inverse agonist radioligands. J Nucl Med 2010; 51: 112-120.
23. Donohue SR, Krushinski JH, Pike VW, Chernet E, Phebus L, Chesterfield AK et al. Synthesis, ex vivo evaluation, and radiolabeling of potent 1,5-diphenylpyrrolidin-2-one cannabinoid subtype-1 receptor ligands as candidates for in vivo imaging. J Med Chem 2008; 51: 5833-5842.
24. Heishman SJ, Singleton EG, Liguori A. Marijuana craving questionnaire: development and initial validation of a self-report instrument. Addiction 2001; 96: 1023-1034. (Pubitemid 32664602)
25. Zoghbi SS, Shetty HU, Ichise M, Fujita M, Imaizumi M, Liow JS et al. PET imaging of the dopamine transporter with 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements. J Nucl Med 2006; 47: 520-527. (Pubitemid 46768495)
26. Gandelman MS, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Innis RB. Evaluation of ultrafiltration for the free-fraction determination of single photon emission computed tomography (SPECT) radiotracers: beta-CIT, IBF, and iomazenil. J Pharm Sci 1994; 83: 1014-1019. (Pubitemid 24228554)
27. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002; 15: 273-289. (Pubitemid 34852226)
28. Burger C, Mikolajczyk K, Grodzki M, Rudnicki P, Szabatin M, Buck A. Java tools for quantitative post-processing of brain PET data. J Nucl Med 1998; 39: 277-278.
29. Friston KJ, Holmes AP, Worsley KJ, Poline JP, Frith C, Frackowiak RSJ. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 1995; 2: 189-210. (Pubitemid 124008664)
30. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27: 1533-1539. (Pubitemid 47301451)
31. Karschner EL, Schwilke EW, Lowe RH, Darwin WD, Herning RI, Cadet JL et al. Implications of plasma Delta9- tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy- THC concentrations in chronic cannabis smokers. J Anal Toxicol 2009; 33: 469-477.
32. Karschner EL, Schwilke EW, Lowe RH, Darwin WD, Pope HG, Herning R et al. Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users? Addiction 2009; 104: 2041-2048.
33. Lowe RH, Abraham TT, Darwin WD, Herning R, Cadet JL, Huestis MA. Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. Drug Alcohol Depend 2009; 105: 24-32.
34. Innis RB, Malison RT, al-Tikriti M, Hoffer PB, Sybirska EH, Seibyl JP et al. Amphetamine-stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates. Synapse 1992; 10: 177-184.
35. Terry G, Liow J, Chernet E, Zoghbi S, Phebus L, Felder C et al. Positron emission tomography imaging using an inverse agonist radioligand to assess cannabinoid CB1 receptors in rodents. Neuroimage 2008; 41: 690-698.
36. Rinaldi-Carmona M, Pialot F, Congy C, Redon E, Barth F, Bachy A et al. Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. Life Sci 1996; 58: 1239-1247. (Pubitemid 26096331)
37. Villares J. Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain. Neuroscience 2007; 145: 323-334. (Pubitemid 46237689)
38. Martin BR, Sim-Selley LJ, Selley DE. Signaling pathways involved in the development of cannabinoid tolerance. Trends Pharmacol Sci 2004; 25: 325-330. (Pubitemid 38692425)
39. D'Souza DC. Cannabinoids and psychosis. Int Rev Neurobiol 2007; 78: 289-326.
40. Cooper ZD, Haney M. Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor. Addict Biol 2008; 13: 188-195. (Pubitemid 351698888)
41. Cota D. CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab Res Rev 2007; 23: 507-517. (Pubitemid 350018024)
42. Bellocchio L, Lafenêtre P, Cannich A, Cota D, Puente N, Grandes P et al. Bimodal control of stimulated food intake by the endocannabinoid system. Nat Neurosci 2010; 13: 281-283.